Melanie DuBois

No más puestos en curso

Health Technology

Consumer Services

Perfil

Melanie DuBois worked as a Director of Quality Assurance at YM BioSciences, Inc. and as a Manager of Quality Assurance at GlaxoSmithKline Pharmaceuticals SA (Belgium).
She received an undergraduate degree from Toronto Metropolitan University in 1987.

Antiguos cargos conocidos de Melanie DuBois.

Empresas	Cargo	Fin
GlaxoSmithKline Pharmaceuticals SA (Belgium) GlaxoSmithKline Pharmaceuticals SA (Belgium) Pharmaceuticals: MajorHealth Technology GlaxoSmithKline Pharmaceuticals SA develops and manufactures pharmaceuticals and vaccines. The company is headquartered in Wavre, Belgium.	Corporate Officer/Principal	01/01/2006
YM BioSciences, Inc. YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada.	Corporate Officer/Principal	-

Ver el detalle de la experiencia de Melanie DuBois.

Formación de Melanie DuBois.

Toronto Metropolitan University of

Undergraduate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Melanie DuBois.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	2
YM BioSciences, Inc. YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada.	Health Technology
GlaxoSmithKline Pharmaceuticals SA (Belgium) GlaxoSmithKline Pharmaceuticals SA (Belgium) Pharmaceuticals: MajorHealth Technology GlaxoSmithKline Pharmaceuticals SA develops and manufactures pharmaceuticals and vaccines. The company is headquartered in Wavre, Belgium.	Health Technology